Viatris (VTRS) said Monday that it filed supplemental new drug applications to Japan's Ministry of Health, Labor and Welfare for approval of Effexor SR Capsules to treat adults with generalized anxiety disorder.
The application follows a phase 3 randomized, double-blind study in Japan which met its primary objective of superiority over a placebo at eight weeks as well as seven secondary efficacy endpoints, the company said.
Effexor is currently approved in Japan to treat major depressive disorder in adults, Viatris said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。